Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NFE2L2 | Q16236 | 8/20 | 0.42 |
| ▸ | NPC1 | O15118 | 2/20 | 0.40 |
| ▸ | RAB9A | P51151 | 2/20 | 0.40 |
| ▸ | PLAU | P00749 | 1/20 | 0.40 |
| ▸ | STAT1 | P42224 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | P4HTM | Q9NXG6 | 1/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
| ▸ | ITGB2 | P05107 | 1/20 | 0.35 |
| ▸ | ICAM1 | P05362 | 1/20 | 0.35 |
| ▸ | ITGAL | P20701 | 1/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.35 |
| ▸ | PTK2 | Q05397 | 1/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Trifluoroacetic Acid SCHEMBL732103 | 1.00 | NFE2L2 (0.42) | NFE2L2NPC1RAB9APLAUSTAT1 | |
| SCHEMBL1124256 | 0.90 | NFE2L2 (0.49) | NFE2L2NPC1RAB9APLAUSTAT1 | |
| SCHEMBL753041 | 0.90 | NFE2L2 (0.49) | NFE2L2NPC1RAB9APLAUSTAT1 | |
| Trifluoroacetic Acid SCHEMBL1970993 | 0.83 | KDM4E (0.41) | NFE2L2RAB9AKDM4ELMNAP4HTM | |
| Trifluoroacetic Acid SCHEMBL1970997 | 0.83 | KDM4E (0.41) | NFE2L2RAB9AKDM4ELMNAP4HTM | |
| Trifluoroacetic Acid SCHEMBL1481977 | 0.80 | P4HTM (0.46) | RAB9ASMN1; SMN2KDM4ELMNAP4HTM | |
| Trifluoroacetic Acid SCHEMBL1481982 | 0.80 | P4HTM (0.46) | RAB9ASMN1; SMN2KDM4ELMNAP4HTM | |
| SCHEMBL732104 | 0.78 | NFE2L2 (0.39) | NFE2L2NPC1RAB9ASTAT1SMN1; SMN2 | |
| SCHEMBL5103902 | 0.78 | EGLN1 (0.47) | NFE2L2NPC1RAB9APLAUSMN1; SMN2 | |
| SCHEMBL4007882 | 0.78 | EGLN1 (0.47) | NFE2L2NPC1RAB9APLAUSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1989196-B1 | PIPERIDINOYLPYRROLIDINES AS MELANOCORTIN TYPE 4 RECEPTOR AGONISTS | PFIZER LTD (GB) | 2013-02-13 | — | — | EP | disclosed |
| US-8138188-B2 | Melanocortin type 4 receptor agonist piperidinoylpyrrolidines | PFIZER INC. (US) | 2012-03-20 | — | — | US | disclosed |
| US-20090036459-A1 | Melanocortin Type 4 Receptor Agonist Piperidinoylpyrrolidines | PFIZER INC | 2009-02-05 | — | — | US | disclosed |
| EP-1989196-A2 | MELANOCORTIN TYPE 4 RECEPTOR AGONIST PIPERIDINOYLPYRROLIDINES | Pfizer Limited (GB) | 2008-11-12 | — | — | EP | disclosed |
| US-20080269233-A1 | Piperidinoyl-Pyrrolidine and Piperidinoyl-Piperidine Compounds | ANDREWS MARK DAVID | 2008-10-30 | — | — | US | disclosed |
| EP-1912968-A1 | PIPERIDINOYL-PYRROLIDINE AND PIPERIDINOYL-PIPERIDINE COMPOUNDS | Pfizer Limited (GB) | 2008-04-23 | — | — | EP | disclosed |
| WO-2007096763-A2 | MELANOCORTIN TYPE 4 RECEPTOR AGONIST PIPERIDINOYLPYRROLIDINES | PFIZER LIMITED (GB) | 2007-08-30 | — | — | WO | disclosed |
| WO-2007015162-A1 | PIPERIDINOYL-PYRROLIDINE AND PIPERIDINOYL-PIPERIDINE COMPOUNDS | PFIZER LIMITED (GB) | 2007-02-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090036459-A1 | Melanocortin Type 4 Receptor Agonist Piperidinoylpyrrolidines | MC4R, MC5R, MC3R | NFE2L2 2931/4885NPC1 2466/4885RAB9A 1334/4885 |
| US-20080269233-A1 | Piperidinoyl-Pyrrolidine and Piperidinoyl-Piperidine Compounds | GPR4, GPR119, PRLHR | NFE2L2 4339/4885NPC1 1079/4885RAB9A 775/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.